Related Experiment Video

Updated: Aug 27, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma

Hongwei Yuan1, Yutong Zhu2, Yalong Cheng1

  • 1College of Life Sciences, Beijing Normal University, Beijing, China; National Institute of Biological Sciences, Beijing, China.

The Journal of Biological Chemistry
|October 2, 2022
PubMed

Insights

Bruton's tyrosine kinase (BTK) mutations inactivate its kinase activity but B-cell malignancies remain dependent on BTK's noncatalytic functions for survival, suggesting new therapeutic strategies targeting BTK degradation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Bruton's tyrosine kinase (BTK) inhibitors are effective treatments for B-cell malignancies.
  • Acquired resistance due to BTK mutations limits long-term efficacy.
  • Understanding resistance mechanisms is crucial for developing novel therapeutic approaches.

Purpose of the Study:

  • To investigate the functional consequences of clinically observed BTK mutations.
  • To explore alternative therapeutic strategies for BTK inhibitor-resistant B-cell malignancies.
  • To identify new dependencies in cancer cells with kinase-inactive BTK.

Main Methods:

  • Structural modeling
  • In vitro kinase assays
  • Deep phospho-tyrosine proteomics
  • CRISPR-Cas9 screening
  • Cellular assays

Main Results:

  • Four clinical BTK mutations (C481F, C481Y, C481R, L528W) inactivate BTK kinase activity.
  • Kinase-inactive BTK does not impair B cell receptor (BCR) signaling, transcription, or cell growth in diffuse large B-cell lymphoma (DLBCL).
  • DLBCL cells with kinase-inactive BTK are sensitive to BTK degradation and show increased dependence on Toll-like receptor 9 (TLR9).

Conclusions:

  • BTK kinase activity is not essential for oncogenic BCR signaling in DLBCL.
  • BTK's noncatalytic function is sufficient to sustain DLBCL survival.
  • Targeting BTK degradation and exploring pathways like TLR9 may overcome resistance in B-cell malignancies.
Keywords:
DLBCLPROTACTLR9kinase-inactive BTKphospho-tyrosine proteomics

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.9K